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South Africa, the country with the largest HIV epidemic worldwide, has been scaling up treatment since 2003 and
is rapidly expanding its eligibility criteria. The HIV treatment programme has achieved significant results, and had
1.8 million people on treatment per 2011. Despite these achievements, it is now facing major concerns regarding
(i) efficiency: alternative treatment policies may save more lives for the same budget; (ii) equity: there are large inequalities
in who receives treatment; (iii) feasibility: still only 52% of the eligible population receives treatment.
Hence, decisions on the design of the present HIV treatment programme in South Africa can be considered suboptimal.
We argue there are two fundamental reasons to this. First, while there is a rapidly growing evidence-base to guide
priority setting decisions on HIV treatment, its included studies typically consider only one criterion at a time and thus
fail to capture the broad range of values that stakeholders have. Second, priority setting on HIV treatment is a highly
political process but it seems no adequate participatory processes are in place to incorporate stakeholders’ views and
evidences of all sorts.
We propose an alternative approach that provides a better evidence base and outlines a fair policy process to improve
priority setting in HIV treatment. The approach integrates two increasingly important frameworks on health care priority
setting: accountability for reasonableness (A4R) to foster procedural fairness, and multi-criteria decision analysis (MCDA)
to construct an evidence-base on the feasibility, efficiency, and equity of programme options including trade-offs. The
approach provides programmatic guidance on the choice of treatment strategies at various decisions levels based on a
sound conceptual framework, and holds large potential to improve HIV priority setting in South Africa.
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With 5.7 million HIV-positive people, South Africa is
the country with the largest HIV epidemic worldwide
[1]. In recent years, the country has gradually expanded
its eligibility criteria for treatment initiation in line with
the World Health Organization (WHO) guidelines [2-6].
It is now rapidly scaling up its treatment programme
aiming to cover all HIV-infected people with a CD4 cell
count of ≤350 μl patients with a TB co-infection, and
HIV-infected pregnant women irrespective of CD4 cell
count [4,7]. The treatment programme has achieved* Correspondence: R.Baltussen@elg.umcn.nl
1Department of Primary and Community Care, Radboud University Nijmegen
Medical Centre, Nijmegen, The Netherlands
Full list of author information is available at the end of the article
© 2013 Baltussen et al.; licensee BioMed Centr
Commons Attribution License (http://creativec
reproduction in any medium, provided the orsignificant results: it is the largest programme of its kind
in the world, with approximately 1.8 million people on
HIV treatment [8].
Despite these achievements, the present HIV programme
is not optimal in three important areas. First, there are
concerns about whether the current treatment strategy
is most efficient. Research suggests that alternative pol-
icies such as universal testing and immediate treatment
of all HIV-infected patients (UTT) [9] and targeting spe-
cific risk groups [10,11], would be more efficient than the
present programme. Second, concerns exist regarding
the equity of the distribution of ART across population
groups – recent reviews show that e.g. men and children
have less access to treatment than women [8,12]. Third,
there are concerns about the programme feasibility givenal Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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2011, 3.4 million people were eligible for treatment in
South Africa, and despite the achievements in scaling up
the treatment programme, yet only 52% of them received
it [8]. This “treatment gap” is related to funding con-
straints, but also due to staff shortages [13], and it will in-
crease with more people surviving on treatment [13,14].
National health authorities acknowledge these concerns
[4] but have not yet developed and implemented treat-
ment guidelines that address these. This results in ad-hoc
priority setting practices (where some clinicians treat pa-
tients on a first-come first-serve basis while others give
preference to the most severely ill) and waiting lists in
parts of the country [15].
In this paper, we argue that the above observations are
related to suboptimal decisions on the design of the
present HIV treatment programme. We argue there are
two fundamental reasons to this. First, while there is a
rapidly growing evidence-base to guide priority setting
decisions on HIV treatment, its included studies typic-
ally consider only one criterion at a time and thus fail to
capture the broad range of values that stakeholders have.
Second, priority setting on HIV treatment is a highly
political process but it seems no adequate participatory
processes are in place to incorporate stakeholders’ views
and evidences of all sorts.
In the paper, we first outline the scientific evidence-
base on HIV treatment priority setting in South Africa,
in terms of efficiency, equity and feasibility. We continue
by proposing an alternative approach based on the com-
bination of two innovative and increasingly important
frameworks for health care priority setting: accountabil-
ity for reasonableness (A4R) to foster fair priority setting
processes, and multi-criteria decision analysis (MCDA)
to foster rational priority setting.
The WHO has recently also recognised the need to
trade-off the mentioned efficiency, equity and feasibility
concerns [16], resulting in “Programmatic guidelines on
HIV treatment” issued in July 2013 [17]. This paper con-
tributes to these guidelines by providing a practical lead
way for making these difficult priority setting decisions
at various decision levels, based on a firm conceptual
framework.
Present approaches to HIV treatment priority setting
Present studies on HIV treatment in South Africa pri-
ority setting typically focus on one of the following
criteria.
Efficiency
Lately, a wide range of mathematical modelling studies
have analysed the population health effects as well as costs
and cost-effectiveness (or efficiency) of early versus late
onset of treatment, many incorporating the transmissionbenefits of ART [11,18-30]. Although models agree that
HIV incidence can be substantially reduced through
expanded access to ART, models differ substantially on
predicted impact and cost-effectiveness of such an inter-
vention [9,31]. In addition, there is a growing interest in
tailoring HIV treatment guidelines to most efficiently tar-
get programmes [10,11].
Equity
Generally speaking, equity in health care pertains to
judgements about distributive equality and the notion
that every individual should have a “fair chance to live a
full healthy life” [32]. Yet, with severely constrained re-
sources as in HIV treatment in South Africa, difficult
ethical choices need to be made on whom is prioritized
for treatment. Only a few studies give normative guid-
ance on this subject. More specifically, Cleary et al. use
the concept of “communitarian claims” in which an indi-
vidual is viewed as having a claim on health care due to
being a member of a community or society—and by ex-
tension, society has some obligation to provide the care
[33]. Claim strength is said to be affected by the severity
of disease (sicker patients would be prioritized for moral
reasons) or the individual capacity to benefit (patients
with a better prognosis would be prioritized as this
would lead to better clinical outcomes). Another claim
stems from the impact of the programme on population
health (patients would be prioritized whose treatment
contributes most to reduction of the epidemic). Obvi-
ously, these above factors lead to conflicting recommen-
dations on treatment initiation, particularly regarding
whether this should be early or late in the course of dis-
ease. Other factors influencing claims include the “social
context” of those in need. Kimmel et al., [15] showed that
professionals in South Africa support prioritizing individ-
ual patients based on treatment adherence, pregnancy
status, and severity of illness.
Scholars take different positions when it comes to
claim strength in the use of antiretrovirals for treatment
or for prevention. Brock and Wikler argue that “the
strongest moral imperative directs us to giving priority
to saving the most lives (..) even if this means lowering
the priority given to the goal of universal access to treat-
ment, to provide maximum protection from HIV infec-
tion” [34]. In response, Macklin and Cowan reason that
“it is unethical to deliberately watch patients with treat-
able HIV/AIDS worsen and die (..) if medication for
treatment are diverted to preexposure prophylaxis” [35].
Alternatively, Singh proposes that a state’s “minimum
core obligation” be used as a guiding principle in HIV
programmes. This would protect the interest of all people,
and as a consequence, antiretrovirals should not be exclu-
sively used for treatment but also for prevention of HIV
among, e.g. vulnerable young women [36].
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Feasibility refers to constraints at the personal and
health system level that may impede the implementation
of HIV treatment programmes. A recent study in South
Africa assessed the human and financial resources re-
quirement for different HIV treatment strategies [14]
but overall there is little systematic guidance on how
these constraints can be considered.
Fundamental weaknesses of present approaches
The above overview shows a rapidly growing evidence-
base on the efficiency, equity and feasibility of HIV treat-
ment in South Africa. Yet, we argue there are two
fundamental weaknesses to the current approaches that
hamper policy makers in their ability to guide priority
setting decisions.
Firstly, the HIV treatment programme in South Africa
is not fully rational, with rational referring to “evidence-
based allocation decisions in health taking into account
all relevant decision-making criteria” [37]. The current
programme is largely based on international guidelines
and does not adequately account for aspects of effi-
ciency, equity, and feasibility – these are not well docu-
mented, difficult to trade-off and therefore typically
considered one at a time. For example, cost-effectiveness
analyses consistently show that UTT is a highly efficient
intervention but thereby ignore the severe health system
capacity constraints of such a strategy, other than the
budget [14]. As another example, the use of pre-exposure
prophylaxis (PrEP) has shown to be effective and cost-
effective to prevent HIV acquisition, but the community
may prioritise to treat those people who are in greatest
need of ART for their own health (even when this is less
cost-effective). It is obvious that studies that fail to simul-
taneously consider efficiency, equity and feasibility con-
cerns also fail to fully inform priority setting decisions
[37]. Underlying reason is that studies are typically not
multidisciplinary (they stem from either clinical medicine,
epidemiology, health economics or ethics), nor interdiscip-
linary (little effort has been made to take into account
community views) [37].
Second, HIV treatment priority setting is a highly pol-
itical process but in the seemingly absence of fair par-
ticipatory processes, stakeholders’ views are typically
not incorporated. The legitimacy of decision-making in
health refers to the use of “generally considered fair condi-
tions for distributive decision-making in health” [38-40]
corresponding to “the belief that authorities, institutions,
and social arrangements are appropriate, proper, and just”
[40]. Experience shows that there is often justifiable dis-
agreement among stakeholders on which values to use in
priority setting decisions [41,42]. Ethicists have realized
there are no absolute truths on principles to guide priority
setting decisions, and argue that decision-makers mustrely instead on a fair process (i.e. procedural fairness) to es-
tablish fair decisions [43,44]. In contrast, the studies – as
referred to above – typically rely on the assumption of
ideal policy-makers, and that the mere provision of quanti-
fied evidence to policy makers leads to justified priority set-
ting decisions.
The resulting picture is that of an ad-hoc priority set-
ting process on HIV treatment (Figure 1, left panel).
An alternative approach
Here we propose an alternative approach to provide a
better evidence base and include a fairer policy process
to improve HIV treatment priority setting in South
Africa. It is based upon two innovative and increasingly
important frameworks to health care priority setting: the
ethical framework on accountability for reasonableness
(A4R) that fosters fair priority setting, and multi-criteria
decision analysis (MCDA) that fosters rational priority set-
ting [37,45-56]. We believe that the integration of the two
frameworks in a single approach holds large potential to
improve fair and rational priority setting (Figure 1, right
panel) [57]. Pilot studies show that decision makers sup-
port the principles of both frameworks [54,58].
Accountability for reasonableness
A4R is generally considered as a leading conceptual
framework on the ethics of health care priority setting.
Based on justice theories of democratic deliberation, it
aims to strengthen the fairness of priority setting deci-
sions [43,44]. Central to the framework is the acceptance
that people may justifiably disagree on what reasons to
consider when priorities are made. In order to narrow
the scope of controversy, A4R relies on “fair deliberative
procedures that yield a range of acceptable answers”
[43]. Therefore, A4R provides structure for decision-
makers to establish priorities for their specific contexts,
while taking into account limited resources and regula-
tory conditions. Its central notion of democratic learning
presumes that a continuous participatory process will
lead to better knowledge and consensus building on cri-
teria for decisions, and thus also strengthening agree-
ment on - or at least acceptance of - decisions. A4R
does not replace any other guideline, planning or deci-
sion making process, but adds procedural principles to
support their implementation. The A4R framework con-
sists of four conditions.
 Relevance. Priority-setting decisions should be based
on evidence, reasons and principles accepted by the
stakeholders as relevant for meeting health needs
fairly in their contexts. Closely linked to this
condition is the inclusion of a broad range of
stakeholders in the decision-making process. Having
a wide range of stakeholders participating in the
Figure 1 Ad-hoc vs. rational and fair priority setting (based on Baltussen et al.) [37].
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relevant reasons and facilitate the implementation of
the decisions made.
 Publicity. Decision makers should make the process
of priority setting transparent including the reasons
behind the decisions. This gives the general public
an opportunity to understand the values of the
choices involved and a possibility to assess whether
the relevant procedures are being followed. Publicity
is important because it facilitates comparison from
case to case to ensure consistency, it invokes appeal
and may improve trust.
 Appeals/Revision. The appeals condition is a
mechanism that provides the public with an
opportunity to dispute and challenge decisions.
Thus, it also offers the decision makers an option to
revise decisions in the light of further arguments.
An appeals mechanism enriches decision-making
process because initial agreement on reasons can be
reassessed in light of new evidence.
 Leadership/enforcement. There must be public or
voluntary regulation of the decision-making processto ensure that relevance, publicity and appeals
mechanisms are enforced and that decisions are
considered as fair. Proper enforcement of fairness in
decision making will ensure that decisions are
acceptable and can be supported by all concerned.
Activities based on such decisions are also likely to
be more effective and sustainable.
Many authors propose A4R as a guiding framework
on the fairness of HIV treatment [33,35,41,42]. Yet, it
has been criticised for being of limited practical use, i.e.
for not detailing the ‘Relevance conditions’, and how to in-
clude relevant evidence in the deliberation process [57,59].
Given the importance of A4R as conceptual framework in
health care priority setting, there is an urgent need to put
it into operation.
Multi-criteria decision analysis
MCDA is theoretically grounded in multi-attribute util-
ity theory [60] and sets programme priorities by referring
to a comprehensive set of explicit criteria and guides deci-
sion makers in understanding the trade-offs between values
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studies on priority setting of HIV treatment, to simultan-
eously consider efficiency, equity and feasibility concerns.
MCDA is routinely used in other disciplines like agri-
culture [61,62], as a response to the observed inability of
people to effectively analyze multiple streams of dissimi-
lar information, but knows relatively few applications in
health. An example of the use of MCDA, in HIV treat-
ment is a study by Cleary et al., [41] in South Africa –
who used mathematical programming techniques to
trade-off equity and efficiency concerns. They estimated
the health effects at different budget levels in the ab-
sence of any equity constraint (“health maximization”),
and in the presence of two equity constraints: “equal
treatment to all”, and “decent minimum”. The conclusion
was that “health maximization” could achieve sizeable
health gains but this would leave a quarter of those eligible
for treatment without care. “Equal treatment” and a “de-
cent minimum” would be more equitable but lead to less
profound health gains. Other studies have used MCDA to
set priorities in HIV/AIDS control in Thailand [51,53] and
Indonesia [63,64].
A core component of any MCDA is the performance
matrix which scores all programme options in terms of
their performance on relevant criteria. Table 1 shows a
hypothetical performance matrix for the evaluation of HIV
treatment programmes. Each row describes a programmeTable 1 Hypothetical and simplified MCDA for HIV treatment
HIV treatment programme option Feasibility† Efficienc
Health system
constraints
Acceptab
How to deliver treatment
Hospital-based treatment •• ••
Facility-based treatment ••• •••
Mobile clinic-based treatment • ••••
Transport subsidies •• ••••
When to initiate treatment
Treatment CD4 < 200 cells/μl ••••• •••
Treatment CD4 < 350 cells/μl ••• •••
Universal test and treat • ••
Who gets targeted for treatment
Discordant couples‡‡ ••• ••
Compliant patient groups‡‡ ••• ••
Pregnant women‡‡ ••• ••••
Productive adults ••• •••
First-come first-serve ••• •
Weights 20 20
†The performance of interventions on efficiency, equity and feasibility is hypothetic
scoring ranges from • to ••••• respectively representing a very weak to very strong p
‡The total is calculated as the weighted scores on all criteria and rounded-off.
‡‡Irrespective of CD4 cell count.option (on how to deliver HIV treatment, when to initiate
treatment, and who gets targeted for treatment) and each
column describes the performance of the options against
the criteria “feasibility”, “efficiency”, and “equity”. For ex-
ample, mobile-clinic based treatment does not perform
well on “efficiency” (as mobile clinics are relatively costly),
but good on “equity” (as it is a way to reach remote areas
and provide treatment to all). The matrix in Table 1 is
highly simplified ― in reality, more criteria may be in-
cluded which makes it adjustable to context. The matrix
also quantifies the detailed performance on all criteria as
well as trade-offs. For example, per programme option, the
matrix may detail the number of life-years averted, among
which population groups these occur, the expected costs,
and required health system capacity―this allows a quanti-
fication of the trade-offs. In addition, in a real life applica-
tion, the programme options in the performance matrix
include coverage levels and can be combined.
There are several ways to interpret the performance
matrix. In a qualitative inspection, any decision maker
simply makes implicit judgments on the weights of the
various criteria. Alternatively, in a quantitative inspec-
tion, any decision maker weighs the different criteria on
the basis of their relative importance, and multiplies the
scores by the weights to obtain weighted averages for all
programmes. Programmes can subsequently be rank-
ordered according to these weighted averages, somehowin South Africa
y† Equity† Other Total‡
ility Costs per
health gain
Fair distribution
of health gains
…..
•• •• ••
••••• •••• ••••
•• ••••• •••
•• ••••• •••
•• •••• •••
•••• ••• •••
••••• • ••
••••• •• •••
••••• • •••
••• ••• ••••
••• • ••
•• • ••
30 30
al and for iIIustrative purposes only. Criteria are example criteria only. The
erformance of an intervention on a certain criteria.
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criteria weights at the bottom row, and weighted averages
in the utter right column, to illustrate the latter; here
facility-based treatment would be ranked first in the choice
on ‘how to deliver treatment’ [37].
The contours of an alternative approach
The integration of the two frameworks in a single ap-
proach holds large potential to improve fair and rational
priority setting [57]. While important frameworks on
themselves, A4R should be informed by better evidence,
and MCDA could be very useful in this regard if
implemented in an accountable and transparent way.
The contours of an alternative approach, including five
phases, are shown in Figure 2. A first phase involves the
formation of a consultation panel consisting of all rele-
vant stakeholders and this may include representatives
from a broad range of parties, such as decision makers,
community representatives, people living with HIV/AIDS,
health professionals, etc., [48,53]. The formation of this
panel can be a gradual process starting with the present
decision-making body.
In a second phase, the panel identifies the decision-
making criteria on the basis of local values. This involves
a deliberative process in which panel members put for-
ward relevant criteria (reasons) for priority setting and
discuss reasons, principles, and evidence that each view
as relevant to making fair decisions about priorities.
These criteria are discussed, and ultimately approved or
rejected, by other panel members. The aim is to reach
acceptance on a set of criteria that are considered rea-
sonable by all panel members. Sometimes this will beFigure 2 The health care priority setting process of HIV treatment prothrough consensus or through democratic voting but other
times through hierarchical decision making. Even these
cases can be compatible with A4R when all values and cri-
teria have been deliberated in a fair way, the rationales for
the decisions are made available and appeals can be made
when the priority setting decision is implemented.
This paper proposes the use of criteria under the gen-
eral headings of “efficiency”, “equity”, and “feasibility”,
but these criteria are obviously not predetermined. In-
stead, these specific criteria should be defined by the
consultation panel as an outcome of stakeholders’ dis-
cussions on which values they find most important in
HIV treatment.
A third phase concerns the construction of the per-
formance matrix, and this is the core component of any
MCDA. In this step, all programme options are scored
in terms of their performance on the selected criteria. In
a fourth phase, the panel interprets the performance
matrix. This may or may not involve the weighing of the
relevant criteria. The A4R framework stipulates that this
phase always includes a component of deliberation to
discuss these weights, to identify any other criteria (that
may have been ignored in the previous phases or that
cannot be quantified), and to address the reasonability of
the final ranking ordering. Phase five is the phase of
evaluating the priority setting decision arrived at, and re-
lates to the transparency, appeal and enforcement condi-
tions of A4R (as described above).
Health care priority setting is a continuous process,
where ethical dilemmas and programme priorities may
regularly need to be updated in the light of changes of
available programme options, of programme characteristicsgrammes - an alternative approach.
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holders’ preferences. Health care priority setting is there-
fore represented here as a cyclical process. The cycle also
reflects that health care priority setting is a (democratic)
interactive learning process, in which the consultation
panel constantly refines the participatory process of identi-
fying, elaborating and deciding on the inclusion of further
relevant stakeholders, criteria and evidence.
Discussion
Balancing efficiency, equity and feasibility in priority set-
ting of HIV treatment is a major challenge, and we have
shown that present approaches fall short in adequately
doing so in South Africa. We propose an alternative ap-
proach that integrates two existing frameworks, and be-
lieve this provides a better evidence base and outlines a
fairer policy process to improve HIV treatment priority
setting in South Africa.
This approach is innovative in a number of ways. Most
importantly, the programme integrates separate disci-
plines of thought on health care priority setting in a sin-
gle framework. The scientific literature of health care
priority setting –whether it is in low-, middle- or high-
income countries– typically does not go beyond the
boundaries of traditional disciplines like medicine, epi-
demiology, health economics and ethics. Our suggested
approach unites insights and methods from these disci-
plines, and merges disease modelling, cost-effectiveness
analysis, equity analysis and procedural fairness in one
single approach. The potential of merging approaches
from different disciplines has been named before by
Peacock et al., who proposed a novel interdisciplinary
framework combining MCDA, A4R, Participatory Action
Research (PAR) and Programme Budgeting and Marginal
Analysis (PMBA) [59]. However, to the best of our know-
ledge, this novel framework has not been explicitly put in
practice. Yet, at the same time, PBMA is reported to rou-
tinely take care of many of the aspects raised above [65].
The approach can be implemented at different political
levels in South Africa including national, province, dis-
trict and community level. Here it provides support for
management and a strategy for quality improvement in
regard to health care priority setting, including a here-
tofore missing evidence-base for these decisions. By
combining the MCDA and A4R, the approach incorpo-
rates many elements that bring a large capacity for con-
siderations. Its implementation results in policies that
are grounded on evidence-based research and that en-
courage involvement from all stakeholders. More im-
portantly it may lead to a greater understanding and
acceptability also from those directly affected by policy
changes [57].
The use of our proposed approach in different decision-
making contexts may lead to the inclusion of differentstakeholders, identification of different criteria and ultim-
ately to the selection of different interventions. While
this may reflect the presence of different values in these
different contexts, it may possibly also reflect differences
in the rigor of implementation of the approach. The de-
velopment of checklists on stakeholders and criteria (as
suggested by Tromp and Baltussen) [66] to consider may
reduce these latter differences. The use of a more stan-
dardized approach including a priori defined criteria (and
possibly even criteria weights) would ignore differences in
values in different contexts, and the importance of the de-
liberative process.
The integration of A4R and MCDA also poses a num-
ber of challenges. First, whereas A4R can be considered
as a continuous democratic governance approach based
on reasons that any stakeholders brings into play, MCDA
requires a higher level of competence for its interpretation.
This may run the risk of leaving out some stakeholders
and limit the influence of others. Yet, first experiences on
the use of MCDA did not identify this as a barrier in the
process [48]. Second, the development of rigour evidence
for health care priority setting, through MCDA, requires
innovative research. Quantitative measures of equity and
feasibility need to be developed, and measures of im-
pact and efficiency need refinement. Also, mathematical
models need to be developed that reflect the performance
of treatment programmes in terms of efficiency and
equity - these models could include measures of feasibility
(as e.g. health workers availability) as health system cap-
acity constraints. Yet, if the latter would be necessary in
any health care priority setting process, MCDA runs the
risk of needing a high level of expertise to provide credible
evidence to the priority setting process. One way of ad-
dressing this is to allow, at least in the beginning of a
process, more reliance on qualitative analysis within the
consultation panel [67,68].Competing interests
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